Showing results (1281-1290 of 3,550) with videos related to

Sort By:
Pageof 355
Thoracic Cancer|September 2, 2020
Radiologic response of chemotherapy alone versus radiation and chemotherapy in the treatment of locally-advanced or advanced thymic epithelial tumorsRobert F Chu, Amira Hussien, Q Kay Li, et al.
Thoracic Cancer|September 4, 2020
EGF+61 A>G polymorphism does not predict response to first-generation EGFR tyrosine kinase inhibitors in lung cancer patientsLeticia F Leal, Ana C Laus, Rodrigo Cavagna, et al.
Thoracic Cancer|November 23, 2020
Diagnostic value of microRNAs for malignant pleural mesothelioma: A mini-reviewYan-Qiu Han, Shang-Cheng Xu, Wen-Qi Zheng, et al.
Thoracic Cancer|November 3, 2020
Thymoma-associated myasthenia gravis: Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymomaAnna De Rosa, Marco Fornili, Michelangelo Maestri Tassoni, et al.
Thoracic Cancer|November 3, 2020
Clinical characteristics and risk factors for in-hospital mortality of lung cancer patients with COVID-19: A multicenter, retrospective, cohort studyLei Nie, Kai Dai, Jiang Wu, et al.
Thoracic Cancer|November 14, 2020
Lung adenocarcinoma with repetitive endotracheal/endobronchial metastasis 20 years after surgery: A case reportYohei Maki, Yoshifumi Kimizuka, Hisashi Sasaki, et al.
Thoracic Cancer|February 15, 2020
Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumabTomoya Fukui, Shinji Hosotani, Itaru Soda, et al.
Thoracic Cancer|February 16, 2020
The preoperative platelet distribution width: A predictive factor of the prognosis in patients with non-small cell lung cancerChang Liu, Hua Zhang, Qi Qi, et al.
Thoracic Cancer|February 18, 2020
Overexpression of JAB1 promotes malignant behavior and predicts poor prognosis in esophageal squamous cell carcinomaQi Shen, Bin Shang, Bin Jiang, et al.
Thoracic Cancer|February 19, 2020
Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trialsMa Honglian, Hui Zhouguang, Peng Fang, et al.
Pageof 355